A cell clumping prevention solution, its preparation method and application

By combining sodium polyglutamate, disodium EDTA, trypsin inhibitors, and poloxamer F68, the batch-to-batch variability and animal-derived contamination issues in preventing cell clumping of the stop solution were resolved, achieving low clumping rate and high cell viability, suitable for flow cytometry and single-cell sequencing.

CN123107899APending Publication Date: 2026-11-17SHENZHEN WINGOR BIO TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611613094.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-19
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing stop solutions have problems such as large batch-to-batch variability, risk of animal-derived contamination, and poor anti-agglomeration ability in preventing cell clumping. In particular, conventional dilution systems cannot effectively prevent high aggregation tendency in cells after trypsin digestion.

Method used

By employing a combination of sodium polyglutamate, disodium EDTA, trypsin inhibitors, and poloxamer F68, multiple mechanisms are formed to prevent cell re-aggregation by chelating calcium ions to block intercellular connections, utilizing negative charge repulsion and steric hindrance effects, and combining with trypsin inhibitors to neutralize residual enzymes.

Benefits of technology

It achieves a cell clumping rate of less than 5% and a cell viability of more than 95%, making it suitable for demanding experiments such as flow cytometry and single-cell sequencing. It also contains no animal-derived components, reducing batch-to-batch variability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107899A_ABST
    Figure CN123107899A_ABST
Patent Text Reader

Abstract

This invention, entitled "A Termination Solution for Preventing Cell Aggregation, Its Preparation Method, and Its Application," belongs to the field of biomedical technology. The technical problem to be solved is to provide a termination solution that is animal-free, has low batch-to-batch variation, and is highly effective in preventing cell aggregation. The key technical points are that the termination solution is free of animal-derived components and contains the following components: sodium polyglutamate (SPG), concentration 0.05%-0.2% (w / v); disodium EDTA, concentration 0.02-0.05 mM; trypsin inhibitor, concentration 0.5-2.0 mg / mL; poloxamer F68, concentration 0.01%-0.05% (w / v); the balance being phosphate buffer, pH 7.2-7.4; the molecular weight of the SPG is 20-80 kDa.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of cell biology technology, specifically relating to a stop solution for preventing cell clumping, its preparation method, and its application. Background Technology

[0002] In cell biology research and clinical applications, it is often necessary to detach adherent cells from the surface of culture dishes to obtain single-cell suspensions. Currently, the most common method is to use proteases such as trypsin to digest intercellular junctions and cell-matrix adhesions. After digestion, it is necessary to promptly terminate the activity of trypsin to prevent over-digestion and cell damage.

[0003] There are two main traditional termination methods: 1. Termination using a culture medium containing 10%-20% fetal bovine serum (FBS): α1-antitrypsin in the serum can neutralize trypsin activity. However, this method has obvious drawbacks: (1) FBS has a complex composition and large batch-to-batch variability, which affects experimental reproducibility; (2) Serum itself contains aggregation-promoting factors and cannot completely prevent cell clumping; (3) There is a risk of animal pathogen contamination from the serum source, making it unsuitable for clinical-grade cell preparation; (4) Proteins in the serum can interfere with the quality of subsequent flow cytometry antibody staining and single-cell sequencing.

[0004] 2. Use phosphate-buffered saline (PBS) to directly dilute and terminate: Although PBS does not contain animal-derived components, it lacks anti-aggregation ability. Cells in PBS are very prone to forming clumps due to cadherin reconstruction, DNA entanglement released from dead cells, etc., with a clumping rate as high as 30%-41%.

[0005] In recent years, those skilled in the art have attempted various improvement schemes: 1. Add DNase I or Benzonase to degrade free DNA: However, enzyme preparations are expensive and require Ca²⁺. + It can activate and has compatibility conflicts with EDTA chelating agents; enzyme residues may also degrade genomic DNA in living cells.

[0006] 2. Using recombinant albumin instead of serum: It has a certain anti-aggregation effect, but albumin mainly works through steric hindrance and is not strong enough to block cadherin-mediated strong adhesion.

[0007] 3. Adding heparin or sodium dextran sulfate: mainly prevents aggregation through negative charge repulsion, but it will affect the subsequent cell adhesion and transfection efficiency.

[0008] Relevant literature retrieved: Patent document CN121702843A (publication date March 20, 2026) discloses a cell dilution buffer comprising: a cell stabilizing and protecting component with a w / v ratio of 0.2%-0.8%, an anti-agglomeration and dispersing component with a w / v ratio of 0.005%-0.02%, an anti-adsorption and inertizing component with a w / v ratio of 0.005%-0.02%, and a buffer conditioning component of 10mM-200mM; the anti-agglomeration and dispersing component in this invention is a natural highly hydrophilic macromolecular polyglutamate sodium (molecular weight between 100-300kDa), and it is stated that this polyglutamate sodium can prevent cell aggregation.

[0009] Patent document CN105705634A (publication date June 22, 2016) discloses a method for preparing three-dimensional cell clusters, which includes the step of transferring the clusters of pluripotent stem cells from the planar adherent culture to a dynamic suspension culture using an enzyme or a chelating agent, wherein the enzyme is a neutral protease and the chelating agent is ethylenediaminetetraacetic acid (EDTA).

[0010] The prior art represented by the aforementioned documents has at least the following unresolved technical problems or defects: While existing technologies have reported the use of sodium polyglutamate (SO4) as an anti-agglomeration component in cell dilution buffer systems to achieve stable cell dispersion, these applications are limited to cell dilution, preservation, and transport buffer scenarios. The use of SO4 in cell termination systems after enzymatic digestion is not publicly disclosed. The cell termination process differs significantly from conventional cell dilution in terms of cell state, reaction system, and technical requirements: after trypsin digestion, cell membrane adhesion structures are disrupted, a large number of cell surface adhesion sites are exposed, and a large amount of free genomic DNA is released. Cell aggregation tendencies are far stronger than in conventional dilution processes, making anti-agglomeration strategies in conventional dilution systems unsuitable for the highly aggregation-prone post-digestion cell systems.

[0011] In addition, existing serum-containing termination systems have problems such as large batch-to-batch variability, residual endogenous aggregation-promoting factors, risk of animal-derived contamination, and interference with subsequent experiments such as flow cytometry and single-cell sequencing. Serum-free PBS dilution termination systems have no anti-aggregation ability and have a high cell clumping rate.

[0012] Therefore, there is an urgent need for a stop solution that is free of animal-derived substances, has low batch-to-batch variation, and effectively prevents cell clumping. Summary of the Invention

[0013] The purpose of this invention is to provide: A stop solution to prevent cell clumping and related technologies are proposed to address the technical problems of existing stop solutions, such as large batch-to-batch variability, risk of animal-derived contamination, and poor anti-agglomeration ability.

[0014] Terminology Explanation: Unless otherwise defined, all technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this subject matter pertains. Unless otherwise stated, all patents, patent inventions, and disclosures cited throughout this document are incorporated herein by reference in their entirety. Where multiple definitions exist for terms herein, the definitions provided in this chapter shall prevail.

[0015] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0016] Definitions of standard chemical terms can be found in the references “Cell Engineering”, by Pang Zeyi et al., Chemical Industry Press, 2004 and “Cell Culture Experiment Manual”, by Liu Yuqin, People’s Military Medical Press, 2009.

[0017] Unless otherwise specified, conventional methods within the scope of the art, such as methods for measuring clumping rate, cell viability, and solution viscosity, shall be used.

[0018] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0019] The term "room temperature" as used in this article refers to ambient temperature, which is between 10 and 30°C. For example, 10°C, 15°C, 20°C, 25°C, 30°C, or any range derived therefrom.

[0020] To achieve the above objectives, the present invention provides the following technical solution: In a first aspect, the present invention provides: a stopping solution for preventing cell clumping, comprising the following components: Sodium polyglutamate (PGA-Na), concentration 0.06%-0.2% (w / v); Disodium ethylenediaminetetraacetate (EDTA), concentration 0.02-0.05 mM; Trypsin inhibitors, at concentrations of 0.5-2.0 mg / mL; Poloxamer F68, concentration 0.01%-0.05% (w / v); The remainder is phosphate buffer solution with a pH of 7.2-7.4; It contains no animal-derived ingredients.

[0021] This invention employs a triple synergistic mechanism to prevent cell clumping, and the predicted mechanism is as follows: First-order biochemical blockade: EDTA chelates Ca 2+ Cadresin cannot rebuild intercellular connections; at the same time, trypsin inhibitors neutralize residual enzymes, preventing further digestion from generating new adhesion sites. Double charge repulsion: The PGA-Na side chain carries a large number of carboxylate negative charges, which increases the zeta potential on the cell surface. With the help of electrostatic repulsion of the same charge, it prevents cells from getting close. Triple steric hindrance: The PGA-Na polymer chains form a hydration film on the cell surface, creating physical isolation so that even if cells accidentally get close, they cannot make direct contact.

[0022] In this invention, the molecular weight of the sodium polyglutamate is 20-80 kDa; preferably 30-70 kDa; and more preferably 40-60 kDa.

[0023] In this invention, the trypsin inhibitor is selected from at least one of soybean trypsin inhibitor (SBTI), aprotinin, and genetically engineered recombinant trypsin inhibitor.

[0024] In some embodiments, the concentration of sodium polyglutamate in the terminating solution is 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.20% (w / v), or a range derived thereof; preferably 0.1%-0.2% (w / v); more preferably 0.1%-0.15% (w / v).

[0025] In some embodiments, the concentration of disodium ethylenediaminetetraacetate in the terminating solution is 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, or a range derived thereof; preferably 0.02-0.04 mM.

[0026] In some embodiments, the concentration of the trypsin inhibitor in the termination solution is 0.5 mg / mL, 0.6 mg / mL, 0.7 mg / mL, 0.8 mg / mL, 0.9 mg / mL, 1.0 mg / mL, 1.1 mg / mL, 1.2 mg / mL, 1.3 mg / mL, 1.4 mg / mL, 1.5 mg / mL, 1.6 mg / mL, 1.7 mg / mL, 1.8 mg / mL, 1.9 mg / mL, 2.0 mg / mL, or a range derived thereof; preferably 0.5-1.5 mg / mL.

[0027] In some embodiments, the concentration of poloxamer F68 in the terminating solution is 0.01%, 0.02%, 0.03%, 0.04%, 0.05% (w / v), or a range derived thereof; preferably 0.01%-0.04% (w / v).

[0028] In some embodiments, the terminating liquid comprises at least one of the following components: Mannitol 5-15mM is used to maintain osmotic pressure stability; Trehalose 1-5mM is used to protect cell membrane integrity; Recombinant human albumin 0.1%-0.5% (w / v) is used to replace animal-derived proteins to provide additional steric hindrance.

[0029] Secondly, the present invention provides a method for preparing the termination liquid, comprising the following steps: Add disodium ethylenediaminetetraacetate and sodium polyglutamate to phosphate buffer, stir to dissolve, then add trypsin inhibitor and poloxamer F68 in sequence, mix well, and filter sterilely.

[0030] Thirdly, the present invention provides the application of the terminating liquid in the following group.

[0031] The group includes at least one of the following: (1) Terminating the digestive effect of trypsin on cells; (2) To prevent cells from re-aggregating and forming cell clumps after dissociation; (3) Preparation of single-cell suspension; (4) Flow cytometry; (5) Single-cell sequencing; (6) Primary cell isolation.

[0032] Fourthly, the present invention provides a cell culture kit comprising the termination solution.

[0033] Fifthly, the present invention provides a method for preventing cell clumping in a single-cell suspension, wherein the termination solution is used for treatment.

[0034] Specifically, the method includes the following steps: adding the stop solution to the digestion solution obtained by enzyme digestion of cells, mixing well, and letting stand.

[0035] Preferably, the method includes the following steps: digesting cells with trypsin to obtain a digestive solution, adding the stop solution to the digestive solution, gently mixing by blowing, and letting it stand at room temperature for 1-5 minutes.

[0036] In some embodiments, the volume ratio of the digestive fluid to the termination fluid is 1:1-3.

[0037] Based on further solutions to the technical problems of the present invention, or simultaneous solutions to multiple technical problems, the preferred solution in the technical solution provided in the first aspect of the present invention includes: The first preferred solution: the optimal dosage relationship of each component. This technical solution, based on the basic formulation of this invention, further reduces the cell clumping rate while maintaining high cell viability and good handling performance.

[0038] The second preferred option is based on the molecular weight limitation of sodium polyglutamate. This technical solution further optimizes the anti-caking effect based on the aforementioned formulation, avoiding the drawbacks of excessively high solution viscosity and operational difficulties caused by excessively high molecular weight.

[0039] Examples 1-10 of this invention at least support the protection range of the termination liquid.

[0040] The termination solution of this invention is summarized from the foregoing explanation and / or the corresponding component ratios in Examples 1-10, based on the common characteristic that it "does not contain animal-derived components, and contains sodium polyglutamate, disodium ethylenediaminetetraacetate, trypsin inhibitor, poloxamer F68, with the balance being phosphate buffer." Therefore, those skilled in the art can reasonably infer that this termination solution, its subordinate concepts, its substantially equivalent technical means, and technical means that can replace non-core auxiliary components based on existing technology and conventional technical means and common knowledge, should all fall within the protection scope of the termination solution of this invention.

[0041] The present invention has at least the following beneficial effects: This invention utilizes the synergistic effect of the anionic charge repulsion of sodium polyglutamate and the steric hindrance effect of flexible polymers, combined with the chelation of calcium ions by EDTA to block cadherin-mediated intercellular adhesion, and the neutralization of residual digestive enzymes by trypsin inhibitors, to effectively prevent the re-aggregation of cells after dissociation.

[0042] Experiments have shown that after treatment with the termination solution of this invention, the cell clumping rate is less than 5% and the cell viability is higher than 95%, which is significantly better than traditional serum-containing termination solutions and PBS termination solutions.

[0043] Meanwhile, this invention does not contain any animal-derived components, has minimal batch-to-batch variation, and is suitable for scenarios requiring high single-cell yields, such as flow cytometry, single-cell sequencing, and primary cell isolation.

[0044] Furthermore, based on the present invention: As can be seen from Example 2, the present invention combines four components—sodium polyglutamate, disodium EDTA, trypsin inhibitor, and poloxamer F68—into a cell termination system after trypsin digestion, achieving a balance between low clumping rate and high cell viability, resulting in an unexpected synergistic effect.

[0045] As demonstrated in Example 8, when the molecular weight of PGA-Na in this invention is in the range of 20-80 kDa, it achieves a good balance between excellent anti-caking effect and suitable solution viscosity, maintaining a high level of cell viability and exhibiting excellent overall operability. However, when the molecular weight reaches 200 kDa, the excessively long molecular chains result in excessively high solution viscosity, making the blowing operation difficult and causing a decrease in cell viability. This proves that the molecular weight of sodium polyglutamate needs to be limited to 20-80 kDa to achieve the comprehensive technical effect of this invention, which balances low clumping rate, high cell viability, and good operability. Attached Figure Description

[0046] Figure 1 Microscopic images of MSC cells after treatment with different stop solutions, 100×; where A is Example 9-1, B is Example 9-2, and C is Example 1.

[0047] Figure 2 The scatter plot shows FSC-A / FSC-H, where A is the stop solution prepared in Example 1 and B is the PBS stop solution. Detailed Implementation

[0048] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0049] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0050] Example 1 A stop solution to prevent cell clumping The formula for the termination solution, calculated per 1L, is shown in Table 1.

[0051] Table 1

[0052] The preparation method of the termination solution includes the following steps: (1) Take 900 mL of PBS (pH 7.4), add EDTA-Na2 powder, and stir magnetically until completely dissolved; (2) Slowly add PGA-Na powder (to avoid clumping), and continue stirring for 30 minutes until completely dissolved. The solution should be transparent and viscous. (3) Add soybean trypsin inhibitor and gently invert to mix (avoid vigorous stirring to prevent air bubbles from forming). (4) Add Pluronic F68 and stir until completely dissolved; (5) Add PBS to a final volume of 1L and filter through a 0.22μm filter membrane for sterilization; (6) Dispense into 50mL sterile centrifuge tubes and store at 4℃. Shelf life is 6 months.

[0053] Test Example 1 Dissociation of human mesenchymal stem cells (MSCs): MSCs were digested with 0.05% trypsin at 37°C for 5 minutes to obtain a digestion solution. A stop solution with a volume of 2 times the digestion solution was added to the digestion solution, and the mixture was gently blown to mix. The mixture was then allowed to stand at room temperature for 2 minutes.

[0054] Example 2 This embodiment is used to verify the synergistic anti-agglomeration effect among the components in the termination solution of the present invention. Based on Example 1, any one component in the formula was omitted to obtain the control systems for each group; human mesenchymal stem cells (MSCs) were used as the experimental cell model, and the cell digestion, processing, and detection observation methods were consistent with those in Test Example 1 of Example 1. The cell agglomeration rate and cell viability after treatment in different groups were measured. The experimental results are shown in Table 2.

[0055] Table 2

[0056] Note: Compared to Example 1, P < 0.01.

[0057] The results showed that, compared with the first group of examples, the absence of any one of the four components led to a significant increase in the agglomeration rate of the stop solution (p<0.01, One-way ANOVA + Tukey test), indicating that the four components were synergistic and indispensable.

[0058] Example 3 This embodiment is based on Example 1, keeping other components and dosages unchanged, and using different anti-polymerization / steric hindrance agents instead of PGA-Na to obtain comparative systems for each group; human mesenchymal stem cells (MSCs) were used as the experimental cell model, and the cell digestion, processing, and detection observation methods were consistent with those in Test Example 1 of Example 1, and the cell aggregation rate and cell viability after treatment of different groups were measured respectively. The experimental results are shown in Table 3.

[0059] Table 3

[0060] Note: Compared to Example 1, P < 0.01.

[0061] The results showed that after replacing sodium polyglutamate with hyaluronic acid, bovine serum albumin, recombinant human albumin, heparin sodium, and dextran sulfate sodium, the cell aggregation rate in all groups was significantly higher than that in Example 1 group (P < 0.01). This indicates that not just any negatively charged macromolecule or sterically hindered substance can achieve excellent anti-aggregation effects in this pancreatic enzyme digestion termination system; sodium polyglutamate in this formulation system has a specific anti-aggregation advantage against cells with a high tendency to aggregate after digestion.

[0062] Example 4 This embodiment is based on Example 1, with other components and dosages kept constant, only the concentration of PGA-Na is changed to obtain the control systems for each group; human mesenchymal stem cells (MSCs) are used as the experimental cell model, and the cell digestion, processing and detection methods are consistent with test example 1 of Example 1, and the cell aggregation rate and cell viability after treatment of different groups are measured respectively. The experimental results are shown in Table 4.

[0063] Table 4

[0064] The results showed that when the PGA-Na concentration was below 0.05% (w / v), the anti-caking effect was significantly insufficient, and the cell clumping rate increased significantly. A concentration in the range of 0.06%-0.20% (w / v) maintained a low clumping rate, high cell viability, and moderate solution viscosity, resulting in excellent overall operability. When the PGA-Na concentration increased to 0.30% (w / v), the solution viscosity became too high, making pipetting difficult, and cell viability decreased. Therefore, a concentration of 0.06%-0.2% (w / v) of polyglutamate is suitable.

[0065] Example 5 This embodiment is based on Example 1, with other components and dosages kept constant, only the concentration of EDTA-Na2 is changed to obtain the control systems for each group; human mesenchymal stem cells (MSCs) are used as the experimental cell model, and the cell digestion, processing and detection methods are consistent with test example 1 of Example 1, and the cell aggregation rate and cell viability after treatment of different groups are measured respectively. The experimental results are shown in Table 5.

[0066] Table 5

[0067] The results showed that when the concentration of EDTA-Na2 was below 0.02 mM, its calcium ion chelating ability was insufficient, and cadherin-mediated cell adhesion was difficult to block effectively, resulting in a significant increase in cell aggregation rate. Within the concentration range of 0.02-0.05 mM, it effectively inhibited cell aggregation while maintaining a high level of cell viability. When the concentration was above 0.05 mM, high concentrations of the chelating agent produced cytotoxicity, leading to a decrease in cell viability. Therefore, EDTA-Na2 at a concentration of 0.02-0.05 mM is suitable.

[0068] Example 6 This embodiment is based on Example 1, with other components and dosages kept constant, only the concentration of soybean trypsin inhibitor is changed to obtain the control systems for each group; human mesenchymal stem cells (MSCs) are used as the experimental cell model, and the cell digestion, processing and detection methods are consistent with test example 1 of Example 1, and the cell aggregation rate and cell viability after treatment of different groups are measured respectively. The experimental results are shown in Table 6.

[0069] Table 6

[0070] The results showed that without the addition of trypsin inhibitors, trypsin could not be fully neutralized, resulting in continuous enzymatic damage to cells, decreased cell viability, and a significantly increased clumping rate. Trypsin inhibitors in the range of 0.5-2.0 mg / mL could effectively neutralize residual trypsin activity, resulting in low clumping rate and high cell viability. Beyond 2.0 mg / mL, further increasing the inhibitor dosage did not provide further benefit in reducing clumping rate or increasing cell viability. Therefore, a trypsin inhibitor concentration of 0.5-2.0 mg / mL is suitable.

[0071] Example 7 This embodiment is based on Example 1, with other components and dosages kept constant, only the concentration of Pluronic F68 is changed to obtain the control systems for each group; human mesenchymal stem cells (MSCs) are used as the experimental cell model, and the cell digestion, processing and detection methods are consistent with test example 1 of Example 1, and the cell aggregation rate and cell viability after treatment of different groups are measured respectively. The experimental results are shown in Table 7.

[0072] Table 7

[0073] The results showed that poloxamer F68 played a supporting role in inhibiting cell clumping; within the concentration range of 0.01%-0.05% (w / v), it synergistically improved cell dispersion without negatively impacting cell viability; at concentrations greater than 0.05% (w / v), the anti-clumping effect was only slightly enhanced, and excessively high concentrations caused a slight decrease in cell viability. Therefore, the optimal concentration of poloxamer F68 is 0.01%-0.05% (w / v).

[0074] Example 8 This embodiment is based on Example 1, with other components and dosages kept constant, except for different molecular weights of PGA-Na (concentration unchanged) to obtain comparative systems for each group; human mesenchymal stem cells (MSCs) were used as the experimental cell model, and the cell digestion, processing, and detection methods were consistent with test example 1 of Example 1, and the cell aggregation rate and cell viability after treatment in different groups were measured respectively. The experimental results are shown in Table 8.

[0075] Table 8

[0076] The results showed that when the molecular weight of sodium polyglutamate was 10 kDa, the steric hindrance effect was insufficient, and the cell aggregation rate increased significantly. A molecular weight in the 20-80 kDa range balanced excellent anti-agglomeration effect, suitable viscosity, and high cell viability, resulting in excellent overall operability. When the molecular weight reached 200 kDa, the molecular chains were too long, the solution viscosity was too high, making the blowing operation difficult and reducing cell viability. This confirms that the molecular weight of sodium polyglutamate needs to be limited to 20-80 kDa to achieve the comprehensive technical effects of this invention.

[0077] Example 9 Human mesenchymal stem cells (MSCs) were used as experimental cell models to compare cell clumping rate and cell viability after different termination solutions. The cell digestion, processing and detection methods were consistent with those in Test Example 1 of Example 1.

[0078] Example 9-1: Sterile pH 7.4 phosphate buffer solution was used as the stop solution; Example 9-2: DMEM medium containing 10% FBS by volume was used as the stop solution; Example 1: The termination solution prepared in Example 1.

[0079] The test results are shown in Table 9 and Figure 1 .

[0080] Table 9

[0081] Note: Compared to Example 1, P < 0.01.

[0082] The results showed that the PBS termination group had a high clumping rate and a significantly reduced cell viability; although the traditional FBS-containing medium termination group had a high cell viability, the clumping rate was still at a high level; the termination solution of the present invention can achieve both low clumping rate and high cell viability, which is significantly better than the two conventional termination methods.

[0083] Example 10 Flow cytometry compatibility verification MSC samples obtained by treatment with the termination solution and PBS of Example 1 of this invention were subjected to flow cytometry analysis. After undergoing the same flow cytometry sample pretreatment, the MSC samples were analyzed, and the single-cell ratio was statistically analyzed using the FSC-A / FSC-H gating strategy. The results are shown in Figure 2.

[0084] Figure 2 In Figure A, the group treated with the termination solution of this invention has a single-cell population of 97.56%; while in Figure B, the PBS termination control group has a single-cell population of only 85.82%. The results indicate that treatment with the termination solution of this invention can yield a higher proportion of single-cell populations. The components of the termination solution do not produce non-specific fluorescence interference, and the antibody staining background is comparable to that of the PBS control group. It exhibits good flow cytometry compatibility and is suitable for downstream experiments such as flow cytometry analysis and single-cell sequencing.

[0085] Verification of technical effectiveness and / or analysis of technical problem solving This invention utilizes the synergistic effect of the anionic charge repulsion of sodium polyglutamate and the steric hindrance effect of flexible polymers, combined with EDTA chelating calcium ions to block cadherin-mediated intercellular adhesion, and trypsin inhibitors neutralizing residual digestive enzymes, to effectively prevent cell re-aggregation after dissociation. Experiments have shown that after treatment with the termination solution of this invention, the cell aggregation rate is less than 5%, and the cell viability is higher than 95%, significantly superior to traditional serum-containing termination solutions and PBS termination solutions.

[0086] Meanwhile, this invention does not contain any animal-derived components, has minimal batch-to-batch variation, and is suitable for scenarios requiring high single-cell yields, such as flow cytometry, single-cell sequencing, and primary cell isolation.

[0087] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A stopping solution for preventing cell clumping, characterized in that, It contains no animal-derived ingredients and includes the following components: Sodium polyglutamate, concentration 0.06%-0.2% (w / v); Disodium ethylenediaminetetraacetate, concentration 0.02-0.05 mM; Trypsin inhibitors, at concentrations of 0.5-2.0 mg / mL; Poloxamer F68, concentration 0.01%-0.05% (w / v); The remainder is phosphate buffer solution with a pH of 7.2-7.4; The molecular weight of the polyglutamate sodium is 20-80 kDa.

2. The terminating liquid according to claim 1, characterized in that, The molecular weight of the polyglutamate sodium is 20-60 kDa; And / or the trypsin inhibitor is selected from at least one of soybean trypsin inhibitor, aprotinin, and genetically engineered recombinant trypsin inhibitor.

3. The terminating liquid according to claim 1, characterized in that, It contains the following components: Sodium polyglutamate, concentration 0.1-0.2% (w / v); Disodium ethylenediaminetetraacetate, concentration 0.02-0.04 mM; Trypsin inhibitors, at a concentration of 0.5-1.5 mg / mL; Poloxamer F68, concentration 0.01%-0.04% (w / v); The remainder is phosphate buffer solution with a pH of 7.2-7.

4.

4. The terminating liquid according to claim 1, characterized in that, It contains the following components: Sodium polyglutamate, concentration 0.1% (w / v); Disodium ethylenediaminetetraacetate, concentration 0.03 mM; Trypsin inhibitor, at a concentration of 1.0 mg / mL; Poloxamer F68, concentration 0.02% (w / v); The remainder is phosphate buffer solution with a pH of 7.2-7.

4.

5. The terminating liquid according to any one of claims 1-4, characterized in that, It contains at least one of the following components: Mannitol 5-15mM; Trehalose 1-5 mM; Recombinant human albumin 0.1%-0.5% (w / v).

6. The method for preparing the terminating liquid according to any one of claims 1-5, characterized in that, The steps include: adding disodium ethylenediaminetetraacetate and sodium polyglutamate to phosphate buffer, stirring to dissolve, then adding trypsin inhibitor and poloxamer F68 in sequence, mixing well, and filtering under sterile conditions.

7. The use of the terminating liquid according to any one of claims 1-5 in the group consisting of, characterized in that, The group includes at least one of the following: (1) Terminating the digestive effect of trypsin on cells; (2) To prevent cells from re-aggregating and forming cell clumps after dissociation; (3) Preparation of single-cell suspension; (4) Flow cytometry; (5) Single-cell sequencing; (6) Primary cell isolation.

8. A cell culture kit, characterized in that, Contains the termination solution according to any one of claims 1-5.

9. A method for preventing cell clumping in a single-cell suspension, characterized in that, The treatment is carried out using the termination solution described in any one of claims 1-5.

10. The method according to claim 9, characterized in that, The process includes the following steps: adding the stop solution to the digestion solution obtained from enzyme digestion of cells, mixing well, and allowing it to stand.

Citation Information

Patent Citations

  • Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells

    CN105705634A

  • Cell dilution buffer solution and application thereof

    CN121702843A